Ubs Asset Management Americas Inc Biotechnology

Ubs Asset Management Americas Inc

$477 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
RCUS Arcus Biosciences, Inc.	$826M	$1.41 Million 0.0% of portfolio	173,598	Q2 2025 Added 78.19%
NUVB Nuvation Bio Inc.	$758M	$1.35 Million 0.0% of portfolio	689,855	Q2 2025 Added 58.25%
ARVN Arvinas, Inc.	$422M	$1.34 Million 0.0% of portfolio	182,611	Q2 2025 Reduced 79.78%
STOK Stoke Therapeutics, Inc.	$867M	$1.22 Million 0.0% of portfolio	107,240	Q2 2025 Added 29.51%
REPL Replimune Group, Inc.	$298M	$1.17 Million 0.0% of portfolio	126,358	Q2 2025 Added 45.64%
DAWN Day One Biopharmaceuticals, Inc.	$549M	$1.14 Million 0.0% of portfolio	175,416	Q2 2025 Added 56.23%
IOVA Iovance Biotherapeutics, Inc.	$376M	$1.13 Million 0.0% of portfolio	657,209	Q2 2025 Reduced 88.62%
ENTA Enanta Pharmaceuticals Inc	$185M	$1.13 Million 0.0% of portfolio	149,178	Q2 2025 Reduced 6.47%
KURA Kura Oncology, Inc.	$545M	$1.09 Million 0.0% of portfolio	189,720	Q2 2025 Added 24.71%
CVAC Cure Vac N.V.	$1B	$1.09 Million 0.0% of portfolio	201,329	Q2 2025 Reduced 28.01%
PHVS Pharvaris N.V.	$737M	$974,000 0.0% of portfolio	55,377	Q2 2025 Reduced 18.96%
BGNE Bei Gene, Ltd.	$23.5B	$960,000 0.0% of portfolio	4,236	Q2 2025 Added 6.27%
CAPR Capricor Therapeutics, Inc.	$151M	$915,000 0.0% of portfolio	92,176	Q2 2025 Added 55.79%
MLTX Moon Lake Immunotherapeutics	$2.1B	$904,000 0.0% of portfolio	19,164	Q2 2025 Reduced 56.25%
PRTA Prothena Corp Public LTD CO	$391M	$845,000 0.0% of portfolio	139,284	Q2 2025 Reduced 63.5%
CGEM Cullinan Oncology, Inc.	$312M	$802,000 0.0% of portfolio	106,580	Q2 2025 Added 32.64%
RCKT Rocket Pharmaceuticals, Inc.	$247M	$701,000 0.0% of portfolio	286,312	Q2 2025 Added 55.02%
LQDA Liquidia Corp	$1.8B	$596,000 0.0% of portfolio	47,896	Q2 2025 Reduced 60.66%
SVRA Savara Inc	$435M	$505,000 0.0% of portfolio	221,669	Q2 2025 Added 39.37%
MGNX Macrogenics Inc	$108M	$264,000 0.0% of portfolio	219,000	Q2 2025 New
BDTX Black Diamond Therapeutics, Inc.	$109M	$248,000 0.0% of portfolio	100,000	Q2 2025 New
ANNX Annexon, Inc.	$101M	$224,000 0.0% of portfolio	93,500	Q2 2025 Added 18.57%
IMCR Immunocore Holdings PLC	$1.61B	$202,000 0.0% of portfolio	6,450	Q2 2025 Added 122.41%
BCYC Bicycle Therapeutics PLC	$208M	$189,000 0.0% of portfolio	27,300	Q2 2025 Added 435.29%
ZLAB Zai Lab LTD	$3.08B	$183,000 0.0% of portfolio	5,250	Q2 2025 Added 337.5%
CDXC Chroma Dex Corp.	$420M	$178,000 0.0% of portfolio	29,142	Q2 2025 New
XERS Xeris Biopharma Holdings, Inc.	$1.06B	$175,000 0.0% of portfolio	37,619	Q2 2025 New
GLUE Monte Rosa Therapeutics, Inc.	$224M	$108,000 0.0% of portfolio	24,100	Q1 2025 New
AKBA Akebia Therapeutics, Inc.	$563M	$99,000 0.0% of portfolio	27,305	Q2 2025 New
ABSI Absci Corp	$233M	$84,000 0.0% of portfolio	32,750	Q2 2025 Added 5.05%
VNDA Vanda Pharmaceuticals Inc.	$257M	$82,000 0.0% of portfolio	17,565	Q2 2025 New
ALT Altimmune, Inc.	$182M	$16,000 0.0% of portfolio	4,215	Q2 2025 Reduced 96.06%
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	325,645	Q2 2025 Added 16.37%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.